COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Nywana Sizemore

Dr. Nywana Sizemore

Scientific Review Officer


Division of Basic and Integrative Biological Sciences DBIB
Oncology 1 Basic Translational OBT
Study Section:
Molecular Oncogenesis MONC

Dr. Nywana Sizemore serves as the Scientific Review Officer of the Cancer Etiology Study Section within the Oncological Sciences Integrated Review Group.

She received her Ph.D. from Case Western Reserve University for her work on the interactions of human papillomavirus and epidermal growth factor signaling in human ectocervical epithelial cells. Her postdoctoral work focused on the role of growth factor signaling in Ras-mediated transformation at Vanderbilt University. The next phase of her work centered on AKT and PTEN signaling in the regulation of the nuclear factor-kappaB (NFkB) transcription factor at the Cleveland Clinic. Before joining CSR in 2008, Dr. Sizemore was an assistant professor in the Department of Cancer Biology at the Cleveland Clinic, where she expanded her research into the investigation of novel targets of the AKT/inhibitor of kappaB kinase (IKK) pathway in colorectal cancer with grant support from NIH.